Search Within

Nikoletta Lendvai

Formats
  1. Meeting Abstract (71)
  2. Journal Article (33)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (106)
  2. Department of Medicine (106)
  3. Hematologic Malignancies, Division of (106)
  4. Myeloma (106)
  5. Hematologic Malignancies Research (77)
  6. Survivorship Research (74)

More Groups

People
  1. Alexander Lesokhin (71)
  2. Hani Hassoun (70)
  3. Heather Landau (68)
  4. Sergio Giralt (67)
  5. David Chung (61)
  6. Carl Landgren (53)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (7)
  4. 2019 (7)
  5. 2018 (14)
  6. 2017 (13)

More Years

Publications
  1. Blood (46)
  2. Biology of Blood and Marrow Transplantation (14)
  3. Leukemia and Lymphoma (9)
  4. Bone Marrow Transplantation (6)
  5. Journal of Clinical Oncology (6)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. American Society of Hematology (47)
  2. Elsevier Inc. (21)
  3. Nature Publishing Group (10)
  4. Taylor & Francis Group (9)
  5. American Society of Clinical Oncology (6)
  6. Ferrata Storti Foundation (5)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase Ib dose escalation trial of sar650984 (anti-cd-38 mab) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Baz, R.; Benson, D.; Lendvai, N.; Vij, R.; Charpentier, E.; Hsu, K.
    Haematologica (2014)

    Fulltext@MSK | Save
  • A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Journal Article

    Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • T-cell depleted allogeneic HSCT for patients with relapsed, high-risk multiple myeloma permits long-lasting remissions in the absence of graft-versus-host disease and provides a platform for adoptive immunotherapeutic approaches
    Meeting Abstract

    Koehne, G.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Phase 1 trial of carfilzomib + melphalan (CarMel) conditioning and autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma (MM)
    Meeting Abstract

    Costa, L. J.; Landau, H.; Venkata, J. K.; Kang, Y. B.; Koehne, G.; Chung, D. J.; Lendvai, N.; Bentz, T.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Immune reconstitution after autologous stem cell transplantation for multiple myeloma
    Meeting Abstract

    Chung, D. J.; Pronschinske, K. B.; Shyer, J. A.; Wu, V.; Hassoun, H.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Koehne, G.; Giralt, S. A.; more...
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Multiple copies of MLL is the most commonly detected cytogenetic abnormality in newly diagnosed multiple myeloma and may modify disease risk
    Meeting Abstract

    Landry, C.; Londono, D.; Devlin, S. M.; Lesokhin, A.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; Jhanwar, S. C.; Giralt, S. A.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma
    Meeting Abstract

    Lesokhin, A.; Gonen, M.; Redling, K.; Lendvai, N.; Hassoun, H.; Landau, H.; Chung, D. J.; Koehne, G.; Patel, M.; Brennan, K. W.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • T-cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed multiple myeloma and high-risk cytogenetics permits long-lasting remissions in the absence of graft-versus-host disease
    Meeting Abstract

    Koehne, G.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S.
    Blood (2013)

    Fulltext@MSK | Save
  • MAGE-A3 recombinant protein (recMAGE-A3) immunotherapy and autologous peripheral blood lymphocyte (PBL) infusion is safe and induces robust humoral immune responses in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (autoSCT)
    Meeting Abstract

    Cohen, A. D.; Lendvai, N.; Gnjatic, S.; Jungbluth, A. A.; Bertolini, S.; Pan, L.; Venhaus, R.; Tsakos, I.; Garcia, K.; Thibodeau, L.; more...
    Blood (2013)

    Fulltext@MSK | Save